Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

Recombinant human erythropoietin (r-HuEpo) has been used for the treatment of renal anemia. With the loss of its patent protection, there has been an upsurge of more affordable biosimilar agents, increasing patient access to treatment for these conditions. The complexity of the manufacturing process...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Kidney international 2011-07, Vol.80 (1), p.88-92
Hauptverfasser:	Praditpornsilpa, Kearkiat, Tiranathanagul, Khajohn, Kupatawintu, Pawinee, Jootar, Saengsuree, Intragumtornchai, Tanin, Tungsanga, Kriang, Teerapornlertratt, Tanyarat, Lumlertkul, Dusit, Townamchai, Natavudh, Susantitaphong, Paweena, Katavetin, Pisut, Kanjanabuch, Talerngsak, Avihingsanon, Yingyos, Eiam-Ong, Somchai
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anemia - drug therapy Anemia - etiology Anemia - immunology anti-r-HuEpo-associated PRCA Antibodies, Neutralizing - biosynthesis Biological and medical sciences biosimilar r-HuEpo chronic kidney disease Erythropoietin - administration & dosage Erythropoietin - adverse effects Erythropoietin - immunology Female Humans Injections, Subcutaneous Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - immunology Kidneys Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Pilot Projects Recombinant Proteins Red-Cell Aplasia, Pure - chemically induced Renal failure Risk Factors Thailand Urinary system involvement in other diseases. Miscellaneous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!